Ref: BHL/ STEX 18/ 2026-27
Date: July 20, 2026

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400001 **Scrip Code: 539872**	National Stock Exchange of India Limited 5th Floor, Exchange Plaza, Bandra Kurla Complex Bandra (East) Mumbai-400051 **Symbol: BAJAJHCARE**

<u>Sub: Outcome of the Board Meeting held on July 20, 2026</u>

Dear Sir/Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ("Listing Regulations") we hereby inform you that the Board of Directors of our Company at its meeting held today i.e. July 20, 2026, has considered and approved the followings:

1. Un-audited Standalone Financial Results of the Company for the quarter ended June 30, 2026 along with the Limited Review Report thereon issued by Walker Chandiok & Co LLP, Chartered Accountants, Statutory Auditors of the Company in accordance with the Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 is attached herewith as '**Annexure A**'.

2. Continuation of directorship of Mr. Gopalakrishnan Kesavan (DIN: 02105656) as a Non-Executive Independent Director of the Company upon attaining the age of 75 years.

Mr. Gopalakrishnan Kesavan is not debarred from holding the office of Director by virtue of any order passed by the Securities and Exchange Board of India or any other such authority in accordance with BSE Circular No. LIST/COMP/14/2018-19 and NSE Circular No. NSE/CML/2018/24 dated 20th June 2018.

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are given in '**Annexure B**'.

We wish to inform you that the Board Meeting commenced today at 5.00 p.m. and concluded at 5.31 p.m.

Kindly take the same on record.

Thanking you.
Yours faithfully,

For and on behalf of Bajaj Healthcare Limited

MONICA TANWAR
Digitally signed by MONICA TANWAR
Date: 2026.07.20 19:22:34 +05'30'

Monica Tanwar
Company Secretary & Compliance Officer
Encl: as above

Walker Chandiok & Co LLP

Walker Chandiok & Co LLP
42nd Floor,
Building Commerz III,
International Business Park,
Oberoi Garden City,
Off Western Express Highway,
Goregaon (East),
Mumbai-400063
T +91 22 6626 2699

Independent Auditor's Review Report on Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Bajaj Healthcare Limited

1. We have reviewed the accompanying statement of unaudited financial results ('the Statement') of **Bajaj Healthcare Limited** ('the Company') for the quarter ended **30 June 2026**, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Walker Chandiok & Co LLP
Chartered Accountants
Firm Registration No: 001076N/N500013

YJain

Yashwant M. Jain
Partner
Membership No. 118782

UDIN:- 26118782CFTTGV7098

Place: Mumbai
Date: 20 July 2026

BAJAJ HEALTHCARE LIMITED

(CIN No.: L99999MH1993PLC072892)

(Reg. and Corp. Office: 602-606, 6th Floor, Bhoomi Velocity Infotech Park, Above ICICI Bank, Road No. 23, Wagle Industrial Estate, Thane (W) - 400 604

(Tel: + 91-22-6617400, Email: investors@bajajhealth.com, Website: www.bajajhealth.com)

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30 JUNE 2026

(Rs. In Lakhs except for Earnings Per Share)

Particulars	Quarter Ended			Year Ended
	30 June 2026	31 March 2026	30 June 2025	31 March 2026
	(Unaudited)	(Refer Note 2)	(Unaudited)	(Audited)
A. Continuing operations				
I. Revenue from operations	16,563.17	15,305.75	14,883.63	61,103.14
II. Other income	81.14	295.62	87.77	713.39
III. Total income (I+II)	**16,644.31**	**15,601.37**	**14,971.40**	**61,816.53**
IV. Expenses				
(a) Cost of materials consumed	9,158.91	9,210.06	6,988.49	30,619.95
(b) Changes in inventories of finished goods and work-in-progress	(549.24)	(1,059.01)	1,070.31	1,019.54
(c) Employee benefits expense	1,747.12	1,630.11	1,435.62	6,275.26
(d) Finance costs	609.10	556.58	522.57	2,223.37
(e) Depreciation and amortisation expense	701.38	762.87	563.65	2,754.84
(f) Other expenses	3,331.21	3,256.98	2,938.25	12,706.61
Total expenses	**14,998.48**	**14,357.59**	**13,518.89**	**55,599.57**
V. Profit before exceptional items and tax expense	**1,645.83**	**1,243.78**	**1,452.51**	**6,216.96**
VI. Exceptional items (Refer Note 5)	-	(3,324.66)	-	(3,324.66)
VII. Profit / (loss) before tax	**1,645.83**	**(2,080.88)**	**1,452.51**	**2,892.30**
VIII. Tax expense				
(a) Current tax	-	-	-	-
(b) Deferred tax	256.55	(139.60)	235.14	761.26
Total tax expense	**256.55**	**(139.60)**	**235.14**	**761.26**
IX. Profit / (loss) after tax from continuing operations	**1,389.28**	**(1,941.28)**	**1,217.37**	**2,131.04**
B. Discontinued operations				
X. Loss before tax from discontinued operations (Refer note 4)	**(26.03)**	**(230.18)**	**(45.43)**	**(511.69)**
XI. Tax impact of discontinued operations	(6.55)	113.60	(11.43)	42.74
XII. Loss after tax from discontinued operations	**(19.48)**	**(343.78)**	**(34.00)**	**(554.43)**
XIII. Profit / (loss) for the period / year (IX + XII)	**1,369.80**	**(2,285.06)**	**1,183.37**	**1,576.61**
XIV. Other comprehensive income				
Continuing operations				
(i) Items that will not be reclassified to profit or loss				
- Remeasurement of defined benefit plans	30.00	6.49	25.00	81.49
(ii) Income tax relating to items that will not be reclassified to profit or loss	(7.55)	(1.63)	(6.29)	(20.51)
Total Other comprehensive income from continuing operations	**22.45**	**4.86**	**18.71**	**60.98**
Discontinued operations				
(i) Items that will not be reclassified to profit or loss	-	-	-	-
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
Total Other comprehensive income from discontinued operations	-	-	-	-
Other comprehensive income for the period / year	**22.45**	**4.86**	**18.71**	**60.98**
XV. Total comprehensive income for the period / year (XIII + XIV))	**1,392.25**	**(2,280.20)**	**1,202.08**	**1,637.59**
XVI. Paid-up equity share capital (Face Value Rs. 5 per share)	1,683.13	1,683.13	1,579.16	1,683.13
XVII. Other equity				51,617.10
XVIII. EPS (Not Annualised except for the year ended 31 March 2026)				
Continuing operations				
(a) Basic EPS (in Rs.)	4.13	(6.08)	3.85	6.73
(b) Diluted EPS (in Rs.)	4.12	(6.07)	3.75	6.72
Discontinued operations				
(a) Basic EPS (in Rs.)	(0.06)	(1.08)	(0.11)	(1.75)
(b) Diluted EPS (in Rs.)	(0.06)	(1.08)	(0.11)	(1.75)
Total operations				
(a) Basic EPS (in Rs.)	4.07	(7.16)	3.74	4.98
(b) Diluted EPS (in Rs.)	4.06	(7.15)	3.64	4.97

WALKER CHANDIOK & Co LLP
MUMBAI
CHARTERED ACCOUNTANTS

BAJAJ HEALTHCARE LTD.

Notes :

1. The above financial results of Bajaj Healthcare Limited (the 'Company') have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on 20 July 2026. These results have been subjected to a limited review by the statutory auditors who have expressed an unmodified review conclusion.

2. The figures for the quarter ended 31 March 2026 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures up to nine months of the relevant financial year.

3. The above un-audited financial results for the quarter ended 30 June 2026 have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standards (Ind AS),as prescribed under Section 133 of the Companies Act 2013 (Act) read with relevant rules issued there under and other accounting principles generally accepted in India in terms of Regulation 33 of the SEBI (Listing obligations and disclosure requirements) Regulations, 2015 as amended.

4. The Company deals in pharmaceuticals products (formulations and active pharmaceutical ingredients components) which are interlinked and interdependent. Therefore, the Company has identified only one reportable segment i.e. Pharmaceuticals.

5. In the year ended 31 March 2024, the Board of Directors had approved to sale/disposal of undertaking/unit(s) on going concern basis, situated at plot no. N-92, L-9/3, T-30, MIDC Tarapur, Taluka- Boisar, District Palghar, Maharashtra and vacant industrial land situated at plot no. D-2/CH/42 & D-2/CH/43 Dahej industrial area, GIDC, Bharuch, Gujarat (which were acquired under SARFAESI ACT, 2022 from Saraswat Bank) and plot no.E-62 and E-63 MIDC Tarapur, Taluka Boisar, District Palghar, Maharashtra. The approval of shareholders was obtained vide postal ballot. The Company has classified the assets and liabilities in relation to these units as Assets and liabilities held for sale/disposal under Ind AS 105 ("Non-current Assets Held for Sale and Discontinued Operations"). The results of the operation of these units have been presented separately on the Statement of Profit and Loss as Discontinued Operations. Out of these, one unit situated at plot no. N-92 was sold during the Quarter ended 31 March 2024 and L-9/3 was sold during the Quarter ended 31 March 2026. The total value of assets classified as held for sale represents lower of carrying value or fair value.

The financial information from discontinued operations:

Particulars	Quarter Ended			Year ended
	30 June 2026	31 March 2026	30 June 2025	31 March 2026
	(Unaudited)	(Refer Note 2)	(Unaudited)	(Audited)
Total Income (A)	-	10.61	2.10	11.71
Total Expenses (B)	26.03	240.79	47.53	523.40
Loss before Tax from Discontinued Operations (C = A - B)	(26.03)	(230.18)	(45.43)	(511.69)
Tax Credit from Discontinued Operations (D)	(6.55)	113.60	(11.43)	42.74
Loss after Tax from Discontinued Operations (E = C - D)	(19.48)	(343.78)	(34.00)	(554.43)

6. On 19 September 2024, the Company allotted 39,84,852 equity shares and 20,79,409 convertible warrants, raising an aggregate amount of Rs. 15,225.90 lakhs. This included 25% of the warrant issue price, amounting to Rs. 1,757.10 lakhs, received at the time of allotment of the convertible warrants.

During the quarter ended 31 March 2026, the Company received the balance 75% of the warrant issue price, aggregating Rs. 5,271.30 lakhs. Subsequently, the Board of Directors, at its meeting held on 18 March 2026, approved the conversion of all 20,79,409 convertible warrants into an equivalent number of fully paid-up equity shares of face value Rs. 5 each.

Pursuant to the aforesaid conversion, the issued, subscribed, and paid-up equity share capital of the Company increased from Rs. 1,579.16 lakhs, comprising 3,15,83,252 equity shares of face value Rs. 5 each, to Rs. 1,683.13 lakhs, comprising 3,36,62,661 equity shares of face value Rs. 5 each.

During the quarter ended 30 June 2026, the Company received approvals from the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) for the listing and trading of the aforesaid 20,79,409 equity shares of face value Rs. 5 each.

The fund raised through allotment of equity shares and convertible warrants under the preferential issue has been utilised for following activities.

Particulars	Amount to be Utilised	Utilised up to 30 June 2026	Unutilised Balance
Repayment of loan	15,000.00	15,000.00	-
Investment in capital expenditure	3,500.00	2,330.84	1,169.16
General corporate purposes	1,997.00	1,993.48	3.52
Total	**20,497.00**	**19,324.32**	**1,172.68**

7. The Company had entered into a Transfer of Technical Know-how arrangement with a customer for one of the products manufactured by the Company. The Technical know-how was ultimately to be used by a customer in Middle East. Due to on-going regional instability in Middle East, the customer was not able to meet its committed timeline. Hence, the Company has reversed the income recognised in earlier year amounting to Rs. 3,324.66 lakhs, in the quarter ended 31 March 2026.

8. In April 2025, the Company acquired Genrx Pharmaceuticals Private Limited (In Liquidation) ("Genrx"), on a going concern basis. Genrx is an existing company incorporated under the provisions of the Companies Act, 1956. The acquisition was made for a total consideration of Rs. 1,085.00 lakhs.

Subsequently, on 3 June 2025, the Company filed an application with the Hon'ble National Company Law Tribunal ('NCLT'), Mumbai, seeking certain reliefs and concessions necessary for the effective implementation of the acquisition and takeover of Genrx as a going concern, which is pending with NCLT as on 30 June 2026. Hence, Genrx has not been considered a subsidiary for consolidation purpose, pending requisite approvals from the NCLT, as control, defined under Ind AS 110 Consolidated Financial Statements is not established.

WALKER CHANDIOK & CO LLP
MUMBAI
CHARTERED ACCOUNTANTS

BAJAJ HEALTHCARE LTD.

For and on behalf of the Board
For Bajaj Healthcare Limited

Anil Champalal Jain
DIN : 00226137
Managing Director

Date : 20 July 2026
Place: Thane

Annexure B

Disclosure pursuant to Para A of Part A of Schedule III of Regulation 30 of Listing Regulations read with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Continuation of Directorship of Mr. Gopalakrishnan Kesavan, Non-Executive Independent Director of the Company:

Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Continuation of current term as Non-Executive Independent Director of the Company upon attaining the age of 75 years on 03rd January 2027 in terms of Regulation 17(1A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, subject to approval of the shareholders.
Date of appointment & Term of appointment	Based on the recommendation of the Nomination & Remuneration Committee, the Board of Directors approved the continuation of current term of Mr. Gopalakrishnan Kesavan (DIN: 02105656) as a Non-Executive Independent Director of the Company upon attaining the age of 75 years subject to approval of Shareholders of the Company. He shall continue to hold office until the expiry of his current term on 17th August 2030.
Brief Profile	Mr. Gopalakrishnan Kesavan holds a B.Sc. in Biology and Chemistry from Kerala University and a Diploma in Management Studies from Mumbai University. He has extensive experience in pharmaceutical sales, marketing, and brand management, having held leadership positions with reputed pharmaceutical companies
Disclosure of relationship Between Directors (in case appointment of a Director)	Mr. Gopalakrishnan Kesavan is not related to any Director of the Company